top of page
Backgrounds.jpg
Statesman-Examiner Logo 2025 with Shadow.png

Loading...

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arvinas, Inc. - Common Stock (NQ:ARVN)

8.190 -0.030 (-0.36%)
Streaming Delayed Price Updated: 9:53 AM EDT, Jul 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 60,576
Open 8.110
Bid (Size) 8.170 (100)
Ask (Size) 8.210 (100)
Prev. Close 8.220
Today's Range 8.100 - 8.220
52wk Range 6.055 - 14.51
Shares Outstanding 63,500,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial Data ↗
Arvinas (NASDAQ:ARVN) management outlined a more selective development strategy at a Jefferies-hosted investor discussion, emphasizing internal investment in neurological and oncology programs where... 
Via MarketBeat

Performance

YTD
-28.6%
-28.6%
1 Month
-1.2%
-1.2%
3 Month
-16.6%
-16.6%
6 Month
-36.7%
-36.7%
1 Year
+9.5%
+9.5%

More News

Read More
News headline image
Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas to Present at Jefferies Global Healthcare Conference
From Arvinas Inc.
Via GlobeNewswire
Arvinas (NASDAQ:ARVN) Q1 2026 Results: First-Ever PROTAC Approval Offsets Revenue Miss ↗
Via Chartmill
Arvinas Inc (NASDAQ:ARVN) Stock Plummets After Q4 2025 Earnings and Revenue Miss Estimates ↗
Via Chartmill
News headline image
Arvinas Employees Give Back During Company-wide Impact Day
From Arvinas Inc.
Via GlobeNewswire
News headline image
These Analysts Increase Their Forecasts On Arvinas After Q1 Results ↗
Via Benzinga
News headline image
Arvinas Q1 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas (ARVN) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas to Participate in Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
From Arvinas Inc.
Via GlobeNewswire
News headline image
ARVN Stock Drops On CEO Exit — Retail Is Bullish On New Chief’s Credentials, Dismisses Selloff ↗
Via Stocktwits
News headline image
Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)
From Arvinas Inc.
Via GlobeNewswire
News headline image
Top movers in Tuesday's session ↗
Via Chartmill

Frequently Asked Questions

Is Arvinas, Inc. - Common Stock publicly traded?
Yes, Arvinas, Inc. - Common Stock is publicly traded.
What exchange does Arvinas, Inc. - Common Stock trade on?
Arvinas, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Arvinas, Inc. - Common Stock?
The ticker symbol for Arvinas, Inc. - Common Stock is ARVN on the Nasdaq Stock Market
What is the current price of Arvinas, Inc. - Common Stock?
The current price of Arvinas, Inc. - Common Stock is 8.190
When was Arvinas, Inc. - Common Stock last traded?
The last trade of Arvinas, Inc. - Common Stock was at 07/30/26 09:53 AM ET
What is the market capitalization of Arvinas, Inc. - Common Stock?
The market capitalization of Arvinas, Inc. - Common Stock is 520.06M
How many shares of Arvinas, Inc. - Common Stock are outstanding?
Arvinas, Inc. - Common Stock has 520M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
bottom of page